Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Quantitative phosphoproteomic analysis of DNA-PK substrates

ABSTRACT: We conducted a TMT based phosphoproteomic analysis to identify DNA-PK substrates.

ORGANISM(S): Homo Sapiens

SUBMITTER: Xiaochun Yu

PROVIDER: PXD039454 | iProX | Sun Jan 15 00:00:00 GMT 2023

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

DNA-PK participates in pre-rRNA biogenesis independent of DNA double-strand break repair.

Li Peng P Gai Xiaochen X Li Qilin Q Yang Qianqian Q Yu Xiaochun X

Nucleic acids research 20240601 11

Although DNA-PK inhibitors (DNA-PK-i) have been applied in clinical trials for cancer treatment, the biomarkers and mechanism of action of DNA-PK-i in tumor cell suppression remain unclear. Here, we observed that a low dose of DNA-PK-i and PARP inhibitor (PARP-i) synthetically suppresses BRCA-deficient tumor cells without inducing DNA double-strand breaks (DSBs). Instead, we found that a fraction of DNA-PK localized inside of nucleoli, where we did not observe obvious DSBs. Moreover, the Ku prot ...[more]

PMID: 38682589

Similar Datasets

Quantitative phosphoproteomic for CDKL5 substrates

Project description:Global phosphoproteomic screen to identify the first cellular substrates of CDKL5. CDKL5 knock-out U2OS cells and CDKL5 wt U2OS cells were generated for the TMT-based phosphoproteomic. Thi leads to the identification and further validation of several phosphopetides of MAP1S, CEP131 and CDKL5 itself. The phosphoproteomic analysis allowed the identification of the first cellular substrates for CDKL5 kinase.

2018-09-24 | PXD009374 | Pride

DNA-PK drives CKD progression by activating TAF7/RAPTOR/mTORC1 signaling-mediated metabolic reprogramming

Project description:Phosphoproteomics profiling of WT and DNA-PKcs-/- mouse kidney tissues was performed to reveal possible substrates of DNA-PK

2022-01-06 | PXD030789 |

Quantitative phosphoproteomic analysis of the molecular substrates of sleep need.

Project description:Sleep and wake have global effects on brain physiology, from molecular changes1-4 and neuronal activities to synaptic plasticity3-7. Sleep-wake homeostasis is maintained by the generation of a sleep need that accumulates during waking and dissipates during sleep8-11. Here we investigate the molecular basis of sleep need using quantitative phosphoproteomic analysis of the sleep-deprived and Sleepy mouse models of increased sleep need. Sleep deprivation induces cumulative phosphorylation of the brain proteome, which dissipates during sleep. Sleepy mice, owing to a gain-of-function mutation in the Sik3 gene 12 , have a constitutively high sleep need despite increased sleep amount. The brain proteome of these mice exhibits hyperphosphorylation, similar to that seen in the brain of sleep-deprived mice. Comparison of the two models identifies 80 mostly synaptic sleep-need-index phosphoproteins (SNIPPs), in which phosphorylation states closely parallel changes of sleep need. SLEEPY, the mutant SIK3 protein, preferentially associates with and phosphorylates SNIPPs. Inhibition of SIK3 activity reduces phosphorylation of SNIPPs and slow wave activity during non-rapid-eye-movement sleep, the best known measurable index of sleep need, in both Sleepy mice and sleep-deprived wild-type mice. Our results suggest that phosphorylation of SNIPPs accumulates and dissipates in relation to sleep need, and therefore SNIPP phosphorylation is a molecular signature of sleep need. Whereas waking encodes memories by potentiating synapses, sleep consolidates memories and restores synaptic homeostasis by globally downscaling excitatory synapses4-6. Thus, the phosphorylation-dephosphorylation cycle of SNIPPs may represent a major regulatory mechanism that underlies both synaptic homeostasis and sleep-wake homeostasis.

| S-EPMC6350790 | biostudies-literature

Synergistic targeting of DNA-PK and KIT signaling pathways in KIT mutant acute myeloid leukemia

Project description:Acute Myeloid Leukemia (AML) is the most common and aggressive form of acute leukemia, with a 5-year survival rate of just 24%. Over a third of all AML patients harbor activating mutations in kinases, such as the receptor tyrosine kinases FLT3 and KIT. FLT3 and KIT mutations are associated with poor clinical outcomes and lower remission rates in response to standard-of-care chemotherapy. We have recently identified that the core kinase of the non-homologous end joining DNA repair pathway, DNA-PK, is activated downstream of FLT3; and targeting DNA-PK sensitized FLT3-mutant AML cells to standard-of-care therapies. Herein, we investigated DNA-PK as a possible therapeutic vulnerability in KIT mutant AML, using isogenic FDC-P1 myeloid progenitor cell lines transduced with an empty vector or oncogenic mutant KIT (V560G, D816V). Targeted quantitative phosphoproteomic profiling identified phosphorylation of DNA-PK at threonine 2599 in KIT mutant cells, indicative of DNA-PK activation. Accordingly, proliferation assays revealed that KIT mutant FDC-P1 cells were more sensitive to the DNA-PK inhibitors M3814 or NU7441, compared to empty vector controls. DNA-PK inhibition combined with inhibition of KIT signaling via using the kinase inhibitors dasatinib or ibrutinib, or the protein phosphatase 2A activators FTY720 or AAL(S), led to synergistic cell death. Discovery phosphoproteomic analysis of KIT-D816V cells revealed that dasatinib single-agent treatment inhibited ERK1 activity, and M3814 single-agent treatment inhibited Akt/mTOR activity. The combination of dasatinib and M3814 treatment inhibited both ERK/MAPK and Akt/mTOR activity, and induced synergistic inhibition of phosphorylation of transcription regulators including MYC and MYB. This study provides insight into the oncogenic pathways regulated by DNA-PK beyond its canonical role in DNA repair, and demonstrates that DNA-PK is a promising novel therapeutic target for KIT mutant cancers.

2023-01-26 | PXD030214 | panorama

The 26S proteasome substrates and the dynamics of nuclear proteome upon DNA damage

Project description:Upon DNA damage, numerous proteins are targeted for ubiquitin-dependent proteasomal degradation. We show that phosphorylation of Rpn10/PSMD4 (ubiquitin receptor of the proteasome) at Ser266, is required for DNA repair. Here, we performed TurboID proximity labeling for capturing the proteasome substrates under DNA damage. Numerous proteins which involve in DNA damage response, chromosome reorganization cell cycle and histone modification were identified as the potential pronuteasome substrates. We find that DNA damage reduced the overall affinity between substrates and wild-type Rpn10 compared to Rpn10-Ser266 mutant cells. Combining TMT quantitative proteomic studies, we observed the dynamics of more than 2,000 nuclear proteins upon DNA damage and time course release. Most proteins were accumulated in wild-type cells in the time course release, while the Rpn10-Ser266 mutant cells show almost no changes in protein level. These findings reveal an inherent self-limiting mechanism of the proteasome that, by controlling substrate recognition through Rpn10 phosphorylation, fine-tunes protein degradation for optimal responses under stress.

2023-11-28 | PXD047298 |

Haemming et al. A lncRNA integrates a DNA-PK-mediated DNA damage response and vascular senescence

Project description:Proteomic analysis on lncRNA associated proteins . Functional role of DNA-PK .

2019-10-04 | MSV000084424 | MassIVE

DNA-PK Phosphoproteomic Profiling during HSV-1 and DNA

Project description:HFF cells were infected with ICP0 RF HSV-1 (MOI 5), treated with bleomycin (10mg/mL), or left untreated as a control. Nu-7441 (DNA-PK inhibitor; 2uM)or DMSO (Control) was applied after 1 hour then samples were harvested after 1 hour for bleomycin treated cells or 6 hours for HSV-1 infected cells.

2024-10-07 | PXD044489 | Pride

Fruquintinib DDI Study With P-gp and BCRP Substrates

Project description:Fruquintinib DDI Study with P-gp and BCRP Substrates

| 2729773 | ecrin-mdr-crc

CDKL5 substrates - Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase

Project description:Identification of CDKL5 substrates. Immuno-precipitated proteins were TMT labelled and analysed via LC-MS/MS.

2018-10-02 | PXD009327 | Pride

Phosphoproteomic screening identifies physiological substrates of dTSSK kinase

Project description:TO identified its potential phosphorylated substrates by investigating differential phosphorylated sites in the testes of wild-type (w1118) and dTSSK-/- male flies using quantitative phosphoproteomic analysis

2023-07-20 | PXD038767 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data